MARKET

SLNO

SLNO

SOLENO THERAPEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.870
-0.090
-4.59%
After Hours: 1.870 0 0.00% 16:08 10/19 EDT
OPEN
1.970
PREV CLOSE
1.960
HIGH
1.990
LOW
1.855
VOLUME
265.19K
TURNOVER
--
52 WEEK HIGH
4.390
52 WEEK LOW
1.180
MARKET CAP
148.84M
P/E (TTM)
-3.0283
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Soleno Therapeutics' Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Soleno Therapeutics.
Zacks · 10/02 15:46
Solid Biosciences, Enlivex Therapeutics leads healthcare gainers, Zosano Pharma, LogicBio Therapeutics among major losers
Gainers: Solid Biosciences (SLDB) +121%, Enlivex Therapeutics (ENLV) +49%, AMAG Pharmaceuticals (AMAG) +45%, ProPhase Labs (PRPH) +14%, Odonate Therapeutics (ODT) +14%.Losers: Zosano Pharma (ZSAN) -54%, LogicBio Therapeutics (LOGC) -31%, Selecta Biosciences (SELB) -31%, Genfit (GNFT) -15%, Soleno Therapeutics (SLNO) -13%.
Seekingalpha · 10/01 15:10
GNW, SELB among premarket losers
Zosano Pharma (ZSAN) -53% after FDA discipline review letter for Qtrypta.Selecta Biosciences (SELB) -44% after SEL-212 misses primary endpoint in mid-stage gout study.LogicBio Therapeutics (LOGC) -26% on launch of equity offering.ChinaNet Online Holdings (CNET) -22%.CynergisTek (CTEK)
Seekingalpha · 10/01 12:16
Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
Updated Results Demonstrate Significant DCCR Exposure Response Relationship Interim Analysis of Open-Label Extension Data Demonstrate Continued EfficacyImprovements in Body Composition and Metabolic Measures Support Efficacy of DCCR in Treatment of PWS SymptomsREDWOOD CITY, Calif., Sept. 30, 2020 (GLOBE
GlobeNewswire · 09/30 19:40
Updated data from Soleno's DCCR late-stage study shows positive outcome in obesity disorder
Soleno Therapeutics ([[SLNO]] +18.8%) announces updated top-line results from Phase 3 trial DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release ((DCCR)) tablets for the treatment of Prader-Willi Syndrome ((PWS)).
Seekingalpha · 09/30 19:39
Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
REDWOOD CITY, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate
GlobeNewswire · 09/15 12:00
Soleno (SLNO) in Focus: Stock Moves 6.3% Higher
Zacks · 08/20 12:35
A Second Look At Soleno Therapeutics
Today, we revisit a small rare disease developmental concern called Soleno Therapeutics.The company recently addressed its near- and medium-term funding terms after a disappointing trial result.A full analysis and investment recommendation is provided in the paragraphs below.
Seekingalpha · 08/17 19:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLNO. Analyze the recent business situations of SOLENO THERAPEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLNO stock price target is 8.33 with a high estimate of 9.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 43.56M
% Owned: 54.73%
Shares Outstanding: 79.59M
TypeInstitutionsShares
Increased
16
10.54M
New
51
12.41M
Decreased
4
374.56K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.82%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Independent Director
Ernest Mario
Chairman/Independent Director
Ernie Mario
President/Chief Executive Officer/Director
Anish Bhatnagar
Chief Financial Officer/Chief Accounting Officer
James Mackaness
Vice President
Patricia Hirano
Vice President
Kristen Yen
Independent Director
William Harris
Independent Director
Gwen Melincoff
Independent Director
Andrew Sinclair
Independent Director
Birgitte Volck
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLNO
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Soleno Therapeutics Inc stock information, including NASDAQ:SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.